Krystal Biotech, Inc. (KRYS)
$341.72-1.40%Close
SELLRECOVERY · day 11
Key stats
Short interest · FINRA settlement 2026-07-31
- Market cap
- $10.1B
- Avg volume
- 376.1K
- Beta
- 0.54
- P/E (TTM)
- 41.32
- Short % float
- 13.67%
- Days to cover
- 4.2
- SI change
- -8.4%
- 1W
- +1.78%
- 1M
- +1.95%
- 3M
- +14.12%
- YTD
- +38.40%
- vs SPY 1W
- +2.97%
- vs SPY 1M
- -1.37%
- vs SPY 3M
- +11.72%
- vs SPY YTD
- +26.64%
Sector peers
Same-sector names ranked by LOPJLB quality proximity · Healthcare
- RPRXBUYRoyalty Pharma plcBULLQ 12$61.33+0.03%
- ASNDSELLAscendis Pharma A/SRECOVERYQ 37$251.95-0.53%
- AVAHBUYAveanna Healthcare Holdings Inc.BULLQ 15$13.71+4.18%
- TRLVBUYRECOVERYQ 14$11.14+0.36%
- SEMSELLSelect Medical Holdings CorporationBULLQ 9$16.51-0.12%
- DGXBUYQuest Diagnostics IncorporatedBULLQ 23$243.87-0.21%
- BMRNBUYBioMarin Pharmaceutical Inc.BULLQ 12$65.07-2.44%
- NVSTBUYEnvista Holdings CorpBEARQ 3$27.34+0.51%
- MDLNSELLMedline Inc.Q -11$34.70+1.28%
- EMBCBUYEmbecta Corp.RECOVERYQ -28$4.99-4.59%
- ENSGBUYThe Ensign Group, Inc.RECOVERYQ 28$179.37-0.06%
- VASOBUYVaso CorporationBULLQ 10$0.29+0.00%
Industry peers
FMP comparable companies · ranked by market cap
- ARWRBUYArrowhead Pharmaceuticals, Inc.$12.3BBULLQ 12$87.47-0.44%
- PTGXBUYProtagonist Therapeutics, Inc.$9.7BBULLQ 33$150.69+0.26%
- PCVXBUYVaxcyte, Inc.$8.9BBULLQ 23$61.34-1.20%
- ALKSSELLAlkermes plc$8.1BBEARQ 6$48.02+1.12%
- TGTXBUYTG Therapeutics, Inc.$7.7BRECOVERYQ 11$50.56+3.21%
- MTSRMetsera, Inc.$7.4B$70.50
- ACLXArcellx, Inc.$6.7B$115.07
- TFXBUYTeleflex Incorporated$6.0BBULLQ 10$134.96-0.37%
- PTCTSELLPTC Therapeutics, Inc.$5.9BRECOVERYQ 19$70.52+1.78%
- CRSPBUYCRISPR Therapeutics AG$5.6BRECOVERYQ 21$58.12-4.07%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 26
- VALUE
- 23
- GROWTH
- 49
- GARP
- 16
- TYPE
- Value / Recovery
Composite of Value · Growth · GARP
ROIC11.6%
REV YoY-
ROE19.3%
EPS YoY-
ROA16.1%
GROSS93
OP45
NET55
[VALUATION]
P/E TTM41.32
P/E FWD-
SECTOR PE22.66
INDUSTRY PE17.07
P/B7.42
P/FCF-
EV/EBITDA44.20
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E0.65
ALTMAN Z-
CURR RATIO8.32
ND/EBITDA-
BETA0.54
